Targets & Mechanisms
With an eye toward M&A, Vivace aims to establish POC for emerging solid tumor target TEAD
Compound could deliver first clinical signal for therapies against Hippo pathway
Vivace’s TEAD inhibitor could deliver the first clinical signal for therapies against the Hippo pathway.
May 4, 2021 | 7:40 PM GMT